Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0EJBII
ADC Name
BL-M07D1
Synonyms
BL M07D1; BLM07D1
   Click to Show/Hide
Organization
Sichuan Baili Pharmaceutical Co., Ltd.; Systimmune, Inc.; Chengdu Bailidote Biological Pharmaceutical Co., Ltd.
Drug Status
Phase 1
Indication
In total 3 Indication(s)
Gastric cancer [ICD11:2B72]
Phase 1
Gastroesophageal cancer [ICD11:2B71]
Phase 1
HER2(+) breast cancer [ICD11:2C60-2C65]
Phase 1
Drug-to-Antibody Ratio
8
Antibody Name
Undisclosed
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05631964
Phase 1
A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and initial efficacy of BL-M07D1 for injection in patients with locally advanced or metastatic digestive tract tumors and other solid tumors.

   Click to Show/Hide
Undisclosed  NCT05461768
Phase 1
A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M07D1 injection in patients with locally advanced or metastatic HER2-positive/low-expression breast cancer and other solid tumors.

   Click to Show/Hide
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05631964  Clinical Status Phase 1
Clinical Description A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and initial efficacy of BL-M07D1 for injection in patients with locally advanced or metastatic digestive tract tumors and other solid tumors.
Experiment 2 Reporting the Activity Date of This ADC [2]
Patients Enrolled
Patients with locally advanced or metastatic HER2-positive/low-expression breast cancer and other solid tumors.
Administration Dosage
.
Related Clinical Trial
NCT Number NCT05461768  Clinical Status Phase 1
Clinical Description A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M07D1 injection in patients with locally advanced or metastatic HER2-positive/low-expression breast cancer and other solid tumors.
References
Ref 1 A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Initial Efficacy of BL-M07D1 for Injection in Patients With Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors, NCT05631964
Ref 2 A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of BL-M07D1injection in Patients With Locally Advanced or Metastatic HER2-positive/Low-expression Breast Cancer and Other Solid Tumors, NCT05461768

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.